| __timestamp | Travere Therapeutics, Inc. | Viridian Therapeutics, Inc. |
|---|---|---|
| Wednesday, January 1, 2014 | 59644696 | 7751000 |
| Thursday, January 1, 2015 | 79541000 | 10251000 |
| Friday, January 1, 2016 | 98015000 | 9575000 |
| Sunday, January 1, 2017 | 103958000 | 10912000 |
| Monday, January 1, 2018 | 103654000 | 11049000 |
| Tuesday, January 1, 2019 | 128951000 | 11646000 |
| Wednesday, January 1, 2020 | 135799000 | 13265000 |
| Friday, January 1, 2021 | 149883000 | 25805000 |
| Saturday, January 1, 2022 | 220206000 | 35182000 |
| Sunday, January 1, 2023 | 265542000 | 94999000 |
Cracking the code
In the dynamic world of biotechnology, understanding the financial strategies of companies is crucial. Over the past decade, Travere Therapeutics, Inc. and Viridian Therapeutics, Inc. have shown distinct patterns in their Selling, General, and Administrative (SG&A) expenses. From 2014 to 2023, Travere Therapeutics increased its SG&A spending by approximately 345%, peaking in 2023. This reflects a strategic investment in growth and operational expansion. In contrast, Viridian Therapeutics, while also increasing its SG&A expenses, showed a more modest growth of around 1,125% over the same period, indicating a more conservative approach. The year 2023 marked a significant leap for Viridian, with expenses reaching nearly 41% of Travere's, highlighting a potential shift in strategy. These trends offer a window into the companies' operational priorities and market positioning strategies.
Selling, General, and Administrative Costs: Alnylam Pharmaceuticals, Inc. vs Viridian Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Summit Therapeutics Inc. and Travere Therapeutics, Inc.
Madrigal Pharmaceuticals, Inc. or Viridian Therapeutics, Inc.: Who Manages SG&A Costs Better?
SG&A Efficiency Analysis: Comparing Corcept Therapeutics Incorporated and Travere Therapeutics, Inc.
Cost Management Insights: SG&A Expenses for Ionis Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Selling, General, and Administrative Costs: Verona Pharma plc vs Travere Therapeutics, Inc.
Rhythm Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.: SG&A Spending Patterns Compared
Who Optimizes SG&A Costs Better? ImmunityBio, Inc. or Viridian Therapeutics, Inc.
Operational Costs Compared: SG&A Analysis of Agios Pharmaceuticals, Inc. and Viridian Therapeutics, Inc.
Breaking Down SG&A Expenses: MannKind Corporation vs Travere Therapeutics, Inc.
SG&A Efficiency Analysis: Comparing Amphastar Pharmaceuticals, Inc. and Travere Therapeutics, Inc.
Cost Insights: Breaking Down Travere Therapeutics, Inc. and Viridian Therapeutics, Inc.'s Expenses